专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06515103B1 Conantokins 失效
标题翻译：柯南托克斯
公开(公告)号：US06515103B1
公开(公告)日：2003-02-04
申请号：US09142080
申请日：2000-05-11
申请人： Fe C. Abogadie , Lourdes J. Cruz , Baldomero M. Olivera , Craig Walker , Clark Colledge , David R. Hillyard , Elsie Jimenez , Richard T. Layer , Li-Ming Zhou , Gregory S. Shen , R. Tyler McCabe , Jean E. Rivier
发明人： Fe C. Abogadie , Lourdes J. Cruz , Baldomero M. Olivera , Craig Walker , Clark Colledge , David R. Hillyard , Elsie Jimenez , Richard T. Layer , Li-Ming Zhou , Gregory S. Shen , R. Tyler McCabe , Jean E. Rivier
IPC分类号： A61K3800
CPC分类号： C07K14/43504 , A61K38/00
摘要： The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.
摘要翻译：本发明涉及具有10-30个氨基酸，包括优选两个或更多个γ-羧基谷氨酸残基的组合蛋白肽，柯南多肽衍生物和柯南鸟肽嵌合体，统称为聚对二聚体。凝血因子可用于治疗神经和精神疾病，例如抗惊厥剂，神经保护剂或止痛剂。

2. 发明授权

US06277825B1 Use of conantokins for treating pain 失效
标题翻译：使用柯南金治疗疼痛
公开(公告)号：US06277825B1
公开(公告)日：2001-08-21
申请号：US09357141
申请日：1999-07-20
申请人： Baldomero M. Olivera , J. Michael McIntosh , R. Tyler McCabe , Richard T. Layer , Li-Ming Zhou
发明人： Baldomero M. Olivera , J. Michael McIntosh , R. Tyler McCabe , Richard T. Layer , Li-Ming Zhou
IPC分类号： A61K3800
CPC分类号： C07K14/43504 , A61K38/00
摘要： The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as pain, e.g., as an analgesic agent.
摘要翻译：本发明涉及使用具有10-30个氨基酸，包括优选两个或更多个γ-羧基谷氨酸残基的共同称为聚对二聚腺嘌呤肽，柯南多肽衍生物和柯南多肽嵌合体用于治疗神经病学和精神疾病如疼痛，例如止痛剂。

3. 发明授权

US06399574B1 Use of conantokins 失效
标题翻译：使用柯南金
公开(公告)号：US06399574B1
公开(公告)日：2002-06-04
申请号：US09533889
申请日：2000-03-22
申请人： R. Tyler McCabe , Li-Ming Zhou , Richard T. Layer , Baldomero M. Olivera , J. Michael McIntosh
发明人： R. Tyler McCabe , Li-Ming Zhou , Richard T. Layer , Baldomero M. Olivera , J. Michael McIntosh
IPC分类号： A61K3800
CPC分类号： C07K14/43504 , A61K38/00
摘要： The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include, epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-complusive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.
摘要翻译：本发明涉及使用具有10-30个氨基酸，包括优选两个或更多个γ-羧基谷氨酸残基的共同称为聚对二聚腺嘌呤肽，柯南多肽衍生物和柯南多肽嵌合体用于治疗神经病学和精神障碍，如抗惊厥剂，神经保护剂或止痛剂。神经系统疾病和精神障碍包括癫痫，惊厥，神经毒性损伤（与缺氧，缺氧或局部缺血，脑卒中，脑或脊髓创伤，心肌梗塞，身体创伤，溺水，窒息，围产期窒息，或低血糖事件），神经变性（与阿尔茨海默病，老年性痴呆，肌萎缩性侧索硬化症，多发性硬化症，帕金森氏病，亨廷顿病，唐氏综合征，柯萨科夫病，精神分裂症，艾滋病痴呆，多发性梗塞性痴呆，Binswanger痴呆和神经元损伤有关不安全的癫痫发作），化学毒性（如成瘾，吗啡耐受，阿片剂耐受性，阿片样物质耐受性和巴比妥耐受性），疼痛（急性，慢性，偏头痛），焦虑，重性抑郁症，躁狂抑郁症，强迫症 - 精神分裂症和情绪障碍（如双相情感障碍，单极痴呆）肌力障碍和季节性有效障碍）和肌张力障碍（运动障碍），睡眠障碍，肌肉松弛和尿失禁。此外，凝血因子可用于治疗艾滋病毒感染，眼科指征和记忆，学习或认知缺陷。

4. 发明授权

US06172041B2 Use of conantokins 失效
标题翻译：使用柯南金
公开(公告)号：US06172041B2
公开(公告)日：2001-01-09
申请号：US09142078
申请日：1999-02-10
申请人： R. Tyler McCabe , Li-Ming Zhou , Richard T. Layer , Baldomero M. Olivera , J. Michael McIntosh
发明人： R. Tyler McCabe , Li-Ming Zhou , Richard T. Layer , Baldomero M. Olivera , J. Michael McIntosh
IPC分类号： A61K3800
CPC分类号： C07K14/43504 , A61K38/00
摘要： The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.
摘要翻译：本发明涉及使用具有10-30个氨基酸，包括优选两个或更多个γ-羧基谷氨酸残基的共同称为聚对二聚腺嘌呤肽，柯南多肽衍生物和柯南多肽嵌合体用于治疗神经病学和精神障碍，如抗惊厥剂，神经保护剂或止痛剂。神经系统疾病和精神疾病包括癫痫，抽搐，神经毒性损伤（与缺氧，缺氧或局部缺血的症状相关，典型地是中风，脑血管意外，脑或脊髓创伤，心肌梗塞，身体创伤，溺水，窒息，围产期窒息或低血糖事件），神经变性（与阿尔茨海默氏病，老年性痴呆，肌萎缩性侧索硬化，多发性硬化症，帕金森病，亨廷顿病，唐氏综合征，柯萨科夫病，精神分裂症，艾滋病痴呆，多发性梗塞性痴呆，Binswanger痴呆和神经元损伤有关不安全的癫痫发作），化学毒性（如成瘾，吗啡耐受，阿片剂耐受，阿片样物质耐受和巴比妥耐受），疼痛（急性，慢性，偏头痛），焦虑，主要抑郁症，躁狂抑郁症，强迫症，精神分裂症和情绪障碍（如双相情感障碍，单极压抑离子，心境恶劣和季节性有效障碍）和肌张力障碍（运动障碍），睡眠障碍，肌肉松弛和尿失禁。此外，凝血因子可用于治疗艾滋病毒感染，眼科指征和记忆，学习或认知缺陷。

5. 发明授权

US11358970B2 Artemisinin-derived trimers and tetramers and their use thereof 有权
公开(公告)号：US11358970B2
公开(公告)日：2022-06-14
申请号：US16755562
申请日：2018-11-21
申请人： Ming Zhao , Li-Ming Zhou
发明人： Ming Zhao , Li-Ming Zhou
IPC分类号： C07D493/18 , A61P35/02 , A61P35/00
摘要： The present disclosure provides compositions comprising artemisinin-derived trimers and tetramers; methods of preparing these compositions; and methods for their use as medicaments.

6. 发明授权

US10987338B2 Composition containing artesunate 有权
公开(公告)号：US10987338B2
公开(公告)日：2021-04-27
申请号：US16572558
申请日：2019-09-16
申请人： Ming Zhao , Li-Ming Zhou
发明人： Ming Zhao , Li-Ming Zhou
IPC分类号： A61K31/357 , A61K31/133 , A61K9/08 , A61K47/18 , A61K47/12 , A61K47/24 , A61K45/06 , A61K9/00 , A61K47/22 , A61K47/26
摘要： The present disclosure provides a composition of artesunate, a process of preparing the same, and a method of treatment.

7. 发明授权

US12083096B2 Composition containing artesunate 有权
公开(公告)号：US12083096B2
公开(公告)日：2024-09-10
申请号：US17207729
申请日：2021-03-21
申请人： Ming Zhao , Li-Ming Zhou
发明人： Ming Zhao , Li-Ming Zhou
IPC分类号： A61K31/357 , A61K9/00 , A61K9/08 , A61K31/133 , A61K45/06 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/26
CPC分类号： A61K31/357 , A61K9/0019 , A61K9/08 , A61K31/133 , A61K45/06 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/26 , Y02A50/30
摘要： The present disclosure provides a corn position of artesunate, a process of preparing the same, and a method of treatment.

8. 发明授权

US07750012B2 Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation 失效
标题翻译：用于治疗炎症的LTA4H的二芳基氮杂环抑制剂
公开(公告)号：US07750012B2
公开(公告)日：2010-07-06
申请号：US11462278
申请日：2006-08-03
申请人： Vincent Sandanayaka , Jasbir Singh , Li-Ming Zhou , Mark E. Gurney
发明人： Vincent Sandanayaka , Jasbir Singh , Li-Ming Zhou , Mark E. Gurney
IPC分类号： A61K31/495 , A61K31/496 , C07D295/15 , C07D333/16 , A61K31/5375 , A61K31/5377 , A61K31/451 , A61K31/4523 , C07D211/34 , C07D211/58 , C07D413/12
CPC分类号： C07D295/033 , C07D211/58 , C07D295/096 , C07D295/15 , C07D333/16 , C07D333/28
摘要： The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
摘要翻译：本发明涉及作为LTA4H（白三烯A4水解酶）抑制剂的联芳基氮连接杂环化学属。这些化合物具有通式，它们可用于治疗和预防和预防炎性疾病和病症。

9. 发明授权

US06284157B1 Process for producing an H2-CO gas mixture 失效
标题翻译：生产H2-CO气体混合物的方法
公开(公告)号：US06284157B1
公开(公告)日：2001-09-04
申请号：US09220604
申请日：1998-12-28
申请人： Baldur Eliasson , Ulrich Kogelschatz , Li-Ming Zhou
发明人： Baldur Eliasson , Ulrich Kogelschatz , Li-Ming Zhou
IPC分类号： C07C102
CPC分类号： C01B3/342 , Y02P20/142
摘要： In a discharge reactor with a low-current gas discharge, an inlet gas made of a CH4—CO2 gas mixture is converted into a synthesis gas having an H2—CO gas mixture which has a higher energy content than the inlet gas. For a predeterminable synthesis gas volume ratio R=H2/CO, the requisite CO2 proportion in the inlet gas can be derived from a function curve (f) or calculated according to V=−4.76·R3+37.57·R2−99.13·R+105.39.
摘要翻译：在具有低电流气体放电的放电反应器中，将由CH 4 -CO 2气体混合物制成的入口气体转化为具有比入口气体更高的能量含量的H 2 -CO气体混合物的合成气。对于可预测的合成气体积比R = H2 / CO，入口气体中所需的CO 2比例可以从函数曲线（f）导出，或根据

10. 发明授权

US10653653B2 Salts of 5-aminolevulinic acid and derivatives 有权
公开(公告)号：US10653653B2
公开(公告)日：2020-05-19
申请号：US16071485
申请日：2017-01-24
申请人： Ming Zhao , Li-Ming Zhou
发明人： Ming Zhao , Li-Ming Zhou
IPC分类号： A61K31/197 , A61K41/00 , A61K47/12 , A61K45/06 , C07C53/16 , C07C229/22 , A61K9/00 , A61K9/06 , A61K9/08 , A61P17/10 , A61P17/06 , A61P35/00
摘要： The present disclosure provides new salts of 5-aminolevulinic acid (5-ALA) and new salts of 5-ALA esters, their preparation, formulation and use as photosensitizing agents in photodynamic therapy, diagnosis and cosmetic cares.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式